Sector: Healthcare | Industry: Biotechnology & Medical Research |
See Regulatory Filings on SEC |
Company Contact | |
Address: | 3000 Pegasus Park Drive, Suite 1430 DALLAS TX 75247 |
Tel: | N/A |
Website: | https://tayshagtx.com |
IR: | See website |
Key People | ||
Sean Patrick Nolan Chairman of the Board, Chief Executive Officer | Sukumar Nagendran President, Head of Research and Development, Director | Kamran Alam Chief Financial Officer |
Business Overview |
Taysha Gene Therapies Inc is a clinical-stage biotechnology company, which is focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system. The Company's lead clinical program, TSHA-102, is in development for the treatment of Rett syndrome, a rare neurodevelopmental disorder. The Company is evaluating TSHA-102 in the REVEALPhase I/II adolescent and adult clinical trial, which is a first-in-human, open-label, randomized, dose escalation and dose-expansion, multicenter study evaluating the safety and preliminary efficacy of TSHA-102 in female patients aged 12-years and older with Rett syndrome. It has acquired a worldwide right to a clinical-stage, intrathecally dosed AAV9 gene therapy program, TSHA-120, for the treatment of giant axonal neuropathy (GAN). It received orphan drug designation from the European Commission for TSHA-120 for the treatment of GAN. |
Financial Overview |
For the fiscal year ended 31 December 2023, Taysha Gene Therapies Inc revenues increased from $2.5M to $15.5M. Net loss decreased 33% to $111.6M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Lower net loss reflects Impairment of long-lived assets decrease of 97% to $1.1M (expense), Research and development - Balancing decrease of 35% to $54.6M (expense). |
Employees: | 52 as of Dec 31, 2023 |
Reporting Currency: | U.S. Dollars |
Enterprise value: | $377.56M as of Dec 31, 2023 |
Annual revenue (TTM): | $15.45M as of Dec 31, 2023 |
EBITDA (TTM): | -$69.91M as of Dec 31, 2023 |
Net annual income (TTM): | -$111.57M as of Dec 31, 2023 |
Free cash flow (TTM): | -$76.89M as of Dec 31, 2023 |
Net Debt Last Fiscal Year: | N/A |
Shares outstanding: | 187,018,275 as of Mar 19, 2024 |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |